Preparation of Reduced Graphene Oxide-Copper Sulfide Composite as Efficient Photothermal Agents for Ablation of Cancer†

doi:10.7503/cjcu20150526

Abstract

Abstract:

A novel reduced graphene oxide-copper sulfide nanoplates(rGO-CuS) composite with photothermal property was synthesized via one-pot hydrothermal method. Structure and morphology of the as-synthesized rGO-CuS nanocomposite were confirmed by transmission electron microscopy(TEM), UV-Vis-NIR and Raman spectroscopy. The rGO-CuS nanocomposite showed enhanced optical absorbance in near infrared region and higher photothermal conversion efficiency than graphene oxide(GO) and CuS nanoplates. The rGO-CuS nanocomposite was further used to photothermal ablation of cancer cells and cancer tissue under a 980 nm laser irradiation and showed improved performance than CuS nanoplates and GO.

Key words: Graphene oxide, Copper sulfide, Nanocomposite, Photothermal treatment, Cancer cell

CLC Number:

O614.12

TrendMD:

KONG Xiangquan, YAN Gang, KUANG Miao, RONG Jianhua. Preparation of Reduced Graphene Oxide-Copper Sulfide Composite as Efficient Photothermal Agents for Ablation of Cancer^†[J]. Chem. J. Chinese Universities, 2016, 37(1): 1.

Figures/Tables 7

Scheme 1 Schematic illustration of the synthesis of rGO-CuS

Fig.1 TEM images of CuS(A) and rGO-CuS(B), HRTEM images of rGO-CuS at different magnifications(C, D)^ Inset in (D) shows the FFT pattern of rGO-CuS.

Fig.2 XRD pattern of rGO-CuS nanoparticles

Fig.3 Raman(A), FTIR(B), UV-Vis-NIR(C) spectra and photothermal heating curves(D) of GO(a), rGO-CuS(b) and CuS(c)^ (D) The samples were dispersed in 200 μL of water respectively with a concentration of 1 mg/mL.

Fig.4 Cytotoxicity evaluation test of MC3T3 cells with different concentrations of GO, CuS and rGO-CuS

Fig.5 Fluorescence microscope images of HeLa cells staind by neutral red without the irradiation of laser(A1—D1, A2—D2) and after treated by the irradiation of 980 nm laser with the power density of 1 W/cm2 over 5 min(A3—D3, A4—D4) for 100 μg/mL rGO-CuS(A1—A4), 100 μg/mL CuS(B1—B4) and 100 μg/mL GO(C1—C4) and control(D1—D4)^(A1—D1), (A3—D3) Dark field; (A2—D2),(A4—D4) bright field.

Fig.6 Quantitative measurement of tumor volumes after treatment^ a. DI water; b. rGO-CuS; c. GO+laser; d. CuS+laser; e. rGO-CuS+laser.

References 20

[1]	Peer D., Karpm J. M., Hong S., Farokhzad O. C., Margalit R., Langer R., Nature Nanotech., 2007, 2(12), 751—760
[2]	Huang X. Q., Tang S. H., Mu X. L., Da Y., Chen G. X., Zhou Z. Y., Ruan F. X., Yang Z. L., Zheng N. F., Nature Nanotech., 2011, 6(1), 28—32
[3]	Tian Q. W., Tang M. H., Sun Y. G., Zou Y. J., Chen Z. G., Zhu M. F., Yang S. P., Wang J. L., Wang J. H., Hu J. Q., Adv. Mater., 2011, 23(31), 3542—3547
[4]	Hu S. H., Chen Y. W., Hung W. T., Chen I. W., Chen S. Y., Adv. Mater., 2012, 24(13), 1748—1754
[5]	Zhang W., Guo Z. Y., Huang D. Q., Liu Z. M., Guo X., Zhong H. Q., Biomaterials,2011, 32(33), 8555—8561
[6]	Robinson J. T., Tabakman S. M., Liang Y. Y., Wang H. L., Casalongue H. S., Vinh D., Dai H. J., J. Am. Chem. Soc., 2011, 133(17), 6825—6831
[7]	Fisher J. W., Sarkar S., Buchanan C. F., Szot C. S., Whitne J., Hatcher H. C., Torti S. V., Rylander C. G., Rylander M. N., Cancer Res., 2010, 70(23), 9855—9864
[8]	Ghosh S., Dutta S., Gomes E., Carroll D., Agostino R. D., Olson J. J., Guthold M., Gmeiner W. H., ACS Nano., 2009, 3(9), 2667—2673
[9]	El-Sayed I. H., Huang X. H., El-Sayed M. A., Cancer Lett., 2006, 239(1), 129—135
[10]	Huang X. H., ElSayed M. A., ElSayed I. H., Qian W., J. Am. Chem. Soc., 2006, 128(6), 2115—2120
[11]	Li Z. M., Huang P., Zhang X. J., Lin J., Yang S., Liu B., Gao F., Xi P., Ren Q. S., Cui D. X., Mol. Pharmaceut., 2009, 7(1), 94—104
[12]	Loo C., Lowery A., Halas N., West J., Drezek R., Nano Lett., 2005, 5(4), 709—711
[13]	Hirsch L. R., Stafford R. J., Sershen S. R., Rivera B., Price R. E., Hazle J. D., Halas N. J., West J. L., PNAS,2003, 100(23), 13549—13554
[14]	Gao L., Fei J. B., Zhao J., Li H., Cui Y., Li J. B., ACS Nano., 2012, 6(9), 8030—8040
[15]	Cobley C. M., Au L., Chen J. Y., Xia Y. N., Expert. Opin. Drug Del., 2010, 7(5), 577—587
[16]	Li Y. B., Lu W., Huang Q. A., Huang M. A., Li C., Chen W., Nanomedicine-UK,2010, 5(8), 1161—1171
[17]	Hessel C. M., Pattani V. P., Rasch M., Panthani M. G., Koo B., Tunnell J. W., Korgel B. A., Nano Lett., 2011, 11(6), 2560—2566
[18]	Zha Z. B., Yue X. L., Ren Q. S., Dai Z. F., Adv. Mater., 2013, 25(5), 777—782
[19]	Shen J., Hu Y., Li C., Chen Q., Small,2009, 5(1), 82—85
[20]	Kuila T., Khanra P., Bose S., Kim N. H., Ku B., Moon B., Lee Z. H., Nanotechnology,2011, 22(30), 305710